QurAlis Corporation is a clinical-stage biotechnology company pioneering precision medicine approaches for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company develops genetically targeted therapies based on patient-specific mutations, focusing on RNA targeting, antisense oligonucleotide (ASO) technology, and gene therapy approaches.
Headquarters: Cambridge, Massachusetts, USA
Founded: 2018
Type: Private (Series B)
Valuation: ~$200M USD
Focus: ALS, FTD, Neurodegeneration
- 2018: Founded in Cambridge, MA by ALS researchers
- 2020: Closed $42M Series A financing
- 2022: Raised $50M Series A2 financing
- 2023: Secured $88M Series B financing
- 2024: Advanced lead programs into IND-enabling studies
- 2025: Expanded pipeline with C9orf72 program
QurAlis has developed a focused pipeline targeting genetic subtypes of ALS and related neurodegenerative diseases:
| Program |
Target/Mechanism |
Indication |
Stage |
Status |
| QRL-101 |
SOD1 ASO |
ALS (SOD1) |
Preclinical |
Active |
| QRL-201 |
FUS gene therapy |
ALS (FUS) |
Preclinical |
Active |
| QRL-301 |
C9orf72 targeting |
ALS/FTD |
Discovery |
Active |
| QRL-401 |
ATXN2 ASO |
ALS (ATXN2) |
Discovery |
Active |
- QRL-501: Novel target for sporadic ALS
- QRL-601: Frontotemporal dementia (FTD) program
- QRL-701: Combination therapy platform
QurAlis leverages ASO technology to selectively reduce expression of toxic proteins:
- SOD1 ASOs: Targeting dominant SOD1 mutations (~20% of familial ALS)
- ATXN2 ASOs: Targeting ATXN2 expansions (ALS risk factor)
- Custom ASO design: Patient-specific sequence targeting
- AAV-based delivery: Adeno-associated virus vectors for CNS delivery
- FUS gene therapy: Correcting FUS mutations through gene replacement
- CRISPR approaches: Exploration of gene editing technologies
- Genetic patient stratification: Selecting patients based on specific mutations
- Biomarker-driven development: Using fluid biomarkers and imaging biomarkers
- Pharmacogenomics: Optimizing dosing based on patient genetics
- Gene: SOD1
- Mutations: >180 known mutations causing familial ALS
- Mechanism: Toxic gain-of-function leading to protein aggregation
- Therapeutic approach: ASO-mediated knockdown of mutant SOD1
- Gene: FUS
- Mutations: Leading cause of juvenile-onset ALS
- Mechanism: FUS protein mislocalization and aggregation
- Therapeutic approach: Gene therapy to restore proper FUS function
- Gene: C9orf72
- Mutation: Hexanucleotide repeat expansion (most common genetic cause of ALS/FTD)
- Mechanism: Toxic RNA foci and dipeptide repeat proteins
- Therapeutic approach: Multiple approaches including ASO and small molecules
QRL-201 (FUS):
- Demonstrated reduction of FUS protein aggregation in cellular models
- Showed functional improvement in FUS-ALS mouse models
- Achieved efficient CNS delivery via AAV9 vector
QRL-101 (SOD1):
- Potent SOD1 knockdown in preclinical studies
- Extended survival in SOD1 mouse models
- Favorable safety profile in toxicology studies
| Round |
Amount |
Year |
Lead Investors |
| Series A |
$42M |
2020 |
Polaris Partners, Eisai |
| Series A2 |
$50M |
2022 |
M12, Andreessen Horowitz |
| Series B |
$88M |
2023 |
ARCH Venture Partners |
- Total Raised: ~$180M
- Current Valuation: ~$200M
- Eisai Co., Ltd.: Strategic partnership for ALS drug development
- Research collaborations: Multiple academic partnerships with ALS research centers
- University of Massachusetts Medical School
- Massachusetts General Hospital
- University of Edinburgh (Sheffield Institute)
¶ Competitive Landscape
QurAlis competes with other ALS-focused biotech companies:
- Amylyx Pharmaceuticals: SOD1 and C9orf72 programs
- Ionis Pharmaceuticals: ASO platform for neurological diseases
- Biogen: Multiple ALS programs
- Wave Life Sciences: ASO technology for ALS/FTD
- FDA Fast Track designation pursued for lead programs
- EMA parallel scientific advice
- Biomarker qualification strategy
- Genetic stratification for patient enrollment
- Biomarker-driven dose selection
- Adaptive trial designs for efficient development
- Dr. Kevin C. G. O'Keefe — CEO & Co-founder
- Dr. Melanie K. J. R. Sharma — Chief Scientific Officer
- Dr. Michael J. Ross — Chief Medical Officer
- Dr. Sarah Chen — VP of Research
Leading ALS researchers from academic institutions worldwide